Boxer Capital’s MacroGenics MGNX Stock Holding History

Boxer Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,245,000	Closed	-$25.7M	–	26
2018 Q2	$25.7M	Sell	1,245,000 -955,000	-43%	-$21.5M	2.91%	14
2018 Q1	$55.4M	Hold	2,200,000	–	–	5.91%	6
2017 Q4	$41.8M	Hold	2,200,000	–	–	7.64%	5
2017 Q3	$40.7M	Buy	2,200,000 +85,000	+4%	+$1.47M	9.26%	4
2017 Q2	$37M	Buy	+2,115,000	New	+$40.3M	8.81%	5

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Boxer Capital's MGNX Position: Q3 2018 in Review

Boxer Capital sold out of MacroGenics (MGNX) in Q3 2018, closing a stake of 1,245,000 shares — an estimated $25.7M sold.

Boxer Capital first reported a position in MGNX in Q2 2017 and held it in 5 quarters. The position peaked at $55.4M in Q1 2018. 130 funds tracked by Wall St. Rank hold MGNX as of Q3 2018.

Boxer Capital reported no remaining MacroGenics position as of Q3 2018 after selling out during the quarter.
Boxer Capital sold 1,245,000 MacroGenics shares in Q3 2018, an estimated $25.7M.
Boxer Capital first reported a position in MacroGenics in Q2 2017 and held it in 5 quarters.
Boxer Capital's MacroGenics position peaked at $55.4M in Q1 2018.
130 funds tracked by Wall St. Rank held MacroGenics as of Q3 2018.

Based on Boxer Capital's 13F filing for Q3 2018, filed 14 Nov 2018.